WO2016024864A1 - Lipid composition for improving behaviour - Google Patents
Lipid composition for improving behaviour Download PDFInfo
- Publication number
- WO2016024864A1 WO2016024864A1 PCT/NL2015/050580 NL2015050580W WO2016024864A1 WO 2016024864 A1 WO2016024864 A1 WO 2016024864A1 NL 2015050580 W NL2015050580 W NL 2015050580W WO 2016024864 A1 WO2016024864 A1 WO 2016024864A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- increasing
- composition
- lipid
- behaviour
- volume
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 222
- 239000000203 mixture Substances 0.000 title claims abstract description 216
- 230000001965 increasing effect Effects 0.000 claims abstract description 101
- 235000016709 nutrition Nutrition 0.000 claims abstract description 76
- 230000000694 effects Effects 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 46
- 230000006399 behavior Effects 0.000 claims abstract description 43
- 235000013311 vegetables Nutrition 0.000 claims abstract description 32
- 230000021824 exploration behavior Effects 0.000 claims abstract description 31
- 150000003904 phospholipids Chemical class 0.000 claims description 47
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 150000001720 carbohydrates Chemical class 0.000 claims description 20
- 235000014633 carbohydrates Nutrition 0.000 claims description 19
- 230000037007 arousal Effects 0.000 claims description 17
- 230000002708 enhancing effect Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000029560 autism spectrum disease Diseases 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 235000021140 nondigestible carbohydrates Nutrition 0.000 claims description 5
- 206010003805 Autism Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 108010071421 milk fat globule Proteins 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 description 31
- 235000005911 diet Nutrition 0.000 description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 230000037213 diet Effects 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 25
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 24
- 235000014113 dietary fatty acids Nutrition 0.000 description 24
- 229930195729 fatty acid Natural products 0.000 description 24
- 239000000194 fatty acid Substances 0.000 description 24
- 150000004665 fatty acids Chemical class 0.000 description 24
- 150000002339 glycosphingolipids Chemical class 0.000 description 22
- 235000019197 fats Nutrition 0.000 description 20
- 235000013336 milk Nutrition 0.000 description 20
- 239000008267 milk Substances 0.000 description 20
- 210000004080 milk Anatomy 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- 235000013350 formula milk Nutrition 0.000 description 19
- 239000011248 coating agent Substances 0.000 description 16
- 238000000576 coating method Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 108010046377 Whey Proteins Proteins 0.000 description 15
- 102000007544 Whey Proteins Human genes 0.000 description 14
- 235000012000 cholesterol Nutrition 0.000 description 14
- 239000007788 liquid Substances 0.000 description 13
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 13
- 235000021342 arachidonic acid Nutrition 0.000 description 12
- 229940114079 arachidonic acid Drugs 0.000 description 12
- 150000002482 oligosaccharides Chemical class 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000005862 Whey Substances 0.000 description 10
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 8
- 235000014121 butter Nutrition 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 235000020256 human milk Nutrition 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 235000015155 buttermilk Nutrition 0.000 description 7
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 7
- 150000002327 glycerophospholipids Chemical class 0.000 description 7
- 239000001814 pectin Substances 0.000 description 7
- 235000010987 pectin Nutrition 0.000 description 7
- 229920001277 pectin Polymers 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 235000021323 fish oil Nutrition 0.000 description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 6
- 229940107187 fructooligosaccharide Drugs 0.000 description 6
- 210000004251 human milk Anatomy 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- -1 diglycerides Chemical class 0.000 description 5
- 150000002190 fatty acyls Chemical group 0.000 description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 5
- 150000003271 galactooligosaccharides Chemical class 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000021243 milk fat Nutrition 0.000 description 5
- 235000021119 whey protein Nutrition 0.000 description 5
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 235000019486 Sunflower oil Nutrition 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 150000002270 gangliosides Chemical class 0.000 description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 4
- 108010028463 kappa-casein glycomacropeptide Proteins 0.000 description 4
- 150000004667 medium chain fatty acids Chemical class 0.000 description 4
- 235000004252 protein component Nutrition 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000002600 sunflower oil Substances 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 230000008133 cognitive development Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 3
- 239000000944 linseed oil Substances 0.000 description 3
- 235000021388 linseed oil Nutrition 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 235000021125 infant nutrition Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003248 quinolines Chemical group 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MUVQIIBPDFTEKM-IUYQGCFVSA-N (2r,3s)-2-aminobutane-1,3-diol Chemical compound C[C@H](O)[C@H](N)CO MUVQIIBPDFTEKM-IUYQGCFVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241001071905 Echium Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical group CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000019904 Raftiline® Nutrition 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 244000077923 Vaccinium vitis idaea Species 0.000 description 1
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical group CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010473 blackcurrant seed oil Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- 229940040387 citrus pectin Drugs 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 125000001924 fatty-acyl group Chemical group 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical group OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 1
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940100557 purslane oil Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229940005741 sunflower lecithin Drugs 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical group CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2240/00—Use or particular additives or ingredients
- A23C2240/05—Milk products enriched with milk fat globule membrane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
Definitions
- the present invention relates to nutritional compositions for infants and young children, in particular infant formulae, which comprises specific lipid ingredients for improving specific aspects of behaviour, such as exploratory behaviour and novelty recognition.
- the nervous system plays an essential role in a mammal's life.
- cognitive, emotional, social, sensory, motoric and regulatory functions are mainly determined by the brain.
- cognitive, emotional, social, sensory, motoric and regulatory functions are mainly determined by the brain.
- Modern nutrition administered during the specific period of infancy when rapid growth and development of the brain occurs has an imprinting or programming effect and therefore has long term consequences on the brain function.
- Breast-fed infants score better on visual and developmental tests than do formula-fed infants and they have an improved neurodevelopment compared to formula fed infants. Also long term links have been reported between breast milk feeding and cognitive ability or neurological status later in life.
- Breast-feeding is the preferred method of feeding infants.
- infant formulae are a good alternative.
- the composition of modern infant formulae is adapted in such a way that it meets many of the special nutritional requirements of the fast growing and developing infant. Still further improvements can be made. Still it seems that improvements can be made towards the constitution of infant milk formulae.
- LC-PUFA long chain polyunsaturated fatty acids
- DHA docosahexaenoic
- AA arachidonic acid
- WO 2009/051502 discloses the use of one or more complex lipids including gangliosides for maintaining or increasing cognitive development in a foetal, infant or child subject.
- WO2006/114790 discloses the use of mixture of polar lipids for improvement of cognitive development in infants or children.
- WO 2009/138680 disclosed the use of a dairy fat source and a vegetable fat source improvement of brain development, cognitive and behavioural functions in infants and small children.
- WO2008/005033 discloses infant formulas with gangliosides, phospholipids, sialic acid, docosahexaenoic acid and arachidonic acid for accelerating brain development, neural migration and cognitive development in infants. In all cases a direct diet effect was disclosed, and no longer term effects.
- WO 2011/115476 and WO 2011/115491 disclose infant nutrition with lipid globules coated with milk phospholipids for use in improving the fatty acid composition of the membrane and of improvement of cognitive or behavioural performance.
- the nutritional composition comprising large lipid globules lead to an improvement in these specific aspects of behaviour. These effects are regulated by specific complex structures of the cognitive brain, such as the cerebral cortex. Without being bound to a theory, it is believed that the nutritional composition comprising lipid globules as defined hereinbelow beneficially affects such complex structures of the brain.
- the invention thus relates to a method for improving behaviour in a human subject, comprising administering a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition to the subject, the nutritional composition comprising lipid globules having (i) a volume-weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour is preferably selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
- the present invention relates to a method for improving behaviour in a human subject, comprising administering a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition to the subject, the nutritional composition comprising lipid globules having (i) a volume-weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour is selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
- the invention can also be worded as the use of a composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition for the manufacture of a nutritional composition for improving behaviour in a human subject, wherein the nutritional composition comprises lipid globules having (i) a volume- weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour is selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
- the invention relates to a nutritional composition
- a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition, for use in improving behaviour
- the nutritional composition comprises lipid globules having (i) a volume-weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour is selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
- the invention relates to a method for improving behaviour by enhancing the effect of novelty induced arousal in a human subject, comprising administering a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition to the subject, the nutritional composition comprising lipid globules having (i) a volume- weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour by enhancing the effect of novelty induced arousal is selected from enhancing the effect of novelty induced arousal on (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
- the invention can also be worded as the use of a composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition for the manufacture of a nutritional composition for improving behaviour by enhancing the effect of novelty induced arousal in a human subject, wherein the nutritional composition comprises lipid globules having (i) a volume-weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour by enhancing the effect of novelty induced arousal is selected from enhancing the effect of novelty induced arousal on (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
- the invention relates to a nutritional composition
- a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition, for use in improving behaviour by enhancing the effect of novelty induced arousal
- the nutritional composition comprises lipid globules having (i) a volume- weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour by enhancing the effect of novelty induced arousal is selected from enhancing the effect of novelty induced arousal on (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
- the invention relates to a method for enhancing the effect of novelty induced arousal on one or more selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity in a human subject, comprising administering a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition to the subject, the nutritional composition comprising lipid globules having (i) a volume- weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid.
- the invention can also be worded as the use of a composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition for the manufacture of a nutritional composition for enhancing the effect of novelty induced arousal on one or more selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity in a human subject, wherein the nutritional composition comprises lipid globules having (i) a volume- weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid.
- the invention relates to a nutritional composition
- a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition, for use in enhancing the effect of novelty induced arousal on one or more selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity in a human subject, wherein the nutritional composition comprises lipid globules having (i) a volume-weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid.
- the method, use or composition for use may be medical or non-medical. In one embodiment, the method, use or composition for use is medical. In one embodiment, the method, use or composition for use is non-medical. Nutritional composition
- the nutritional composition according to the invention comprises a lipid component, comprising 5 - 50 wt% vegetable lipid based on total dry weight of the composition.
- the composition comprises lipid in the form of lipid globules. It is preferred that the nutritional composition according to the invention further comprises protein and digestible carbohydrates, more preferably also one or more further components selected from non-digestible carbohydrates, vitamins, minerals, nucleotides is comprised in the nutritional composition according to the invention.
- the present composition is preferably particularly suitable for providing the daily nutritional requirements to a human with an age below 36 months, particularly an infant with the age below
- the nutritional composition is for feeding or is used for feeding a human subject.
- the present composition comprises a lipid, and preferably a protein and preferably a digestible carbohydrate component wherein the lipid component preferably provides 30 to 60 % of total calories, the protein component preferably provides 5 to 20%, more preferably 5 to 15 wt.%, of the total calories and the digestible carbohydrate component preferably provides
- the present composition comprises a lipid component providing 35 to 50% of the total calories, a protein component provides 6 to 12% of the total calories and a digestible carbohydrate component provides 40 to 60% of the total calories.
- the amount of total calories is determined by the sum of calories derived from protein, lipids and digestible carbohydrates.
- the nutritional composition is preferably an infant nutrition or infant food products, more preferably the nutritional composition is an infant formula composition.
- the present composition is not human breast milk, since the present composition comprises vegetable lipids.
- the nutritional composition of the invention preferably comprises further beneficial components according to international directives for infant formulae, preferably at least one selected from non-digestible carbohydrates, vitamins, minerals and nucleotides.
- the composition is a powder suitable for making a liquid composition after reconstitution with an aqueous solution, preferably with water.
- the composition is a powder to be reconstituted with water. It was found that the size and the coating with polar lipids of the lipid globules remained the same after the drying step and subsequent reconstitution.
- the composition preferably comprises 50 to 200 kcal/100 ml liquid, more preferably 60 to 90 kcal/100 ml liquid, even more preferably 60 to 75 kcal/100 ml liquid.
- This caloric density ensures an optimal ratio between water and calorie consumption.
- the osmolarity of the present composition is preferably between 150 and 420 mOsmol/1, more preferably 260 to 320 mOsmol/1.
- the low osmolarity aims to reduce the gastrointestinal stress. Such stress can induce adipocyte formation.
- the composition is in a liquid form, with a viscosity below 35 mPa.s, more preferably below 6 mPa.s as measured in a Brookfield viscometer at 20°C at a shear rate of 100 s "1 .
- the composition is in a powdered from, which can be reconstituted with water to form a liquid, or in a liquid concentrate form, which should be diluted with water.
- the preferred volume administered on a daily basis is in the range of about 80 to 2500 ml, more preferably about 450 to 1000 ml per day.
- the present composition comprises lipid.
- the lipid provides preferably 30 to 60 % of the total calories of the composition, more preferably providing 35 to 55% of the total calories, even more preferably providing 40 to 50% of the total calories.
- the composition preferably comprises 2.1 to 6.5 g lipid per 100 ml, more preferably 3.0 to 4.0 g per 100 ml. Based on dry weight the present composition preferably comprises 10 to 50 wt.%, more preferably 12.5 to 40 wt.% lipid, even more preferably 19 to 30 wt.% lipid.
- Lipids include polar lipids (such as phospholipids, glycolipids, sphingomyelin, and cholesterol), monoglycerides, diglycerides, triglycerides and free fatty acids.
- the composition comprises at least 75 wt. %, more preferably at least 85 wt.% triglycerides based on total lipids.
- the lipid of the present invention comprises vegetable lipids. The presence of vegetable lipids advantageously enables an optimal fatty acid profile, high in (poly)unsaturated fatty acids and/or more reminiscent to human milk fat. Using lipids from cow's milk alone, or other domestic mammals, does not provide an optimal fatty acid profile.
- the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil (flaxseed oil), rape seed oil (such as colza oil, low erucic acid rape seed oil and canola oil), salvia oil, perilla oil, purslane oil, lingonberry oil, sea buckthorn oil, hemp oil, sunflower oil, high oleic sunflower oil, safflower oil, high oleic safflower oil, olive oil, black currant seed oil, echium oil, coconut oil, palm oil and palm kernel oil.
- linseed oil flaxseed oil
- rape seed oil such as colza oil, low erucic acid rape seed oil and canola oil
- salvia oil such as colza oil, low erucic acid rape seed oil and canola oil
- perilla oil purslane oil
- lingonberry oil sea buckthorn oil
- hemp oil sunflower oil
- the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil, canola oil, coconut oil, sunflower oil and high oleic sunflower oil.
- Commercially available vegetable lipids are typically offered in the form a continuous oil phase.
- the composition preferably comprises 1.0 to 7.0 g, more preferably 2.1 to 6.5 g vegetable lipid per 100 ml, more preferably 3.0 to 4.0 g per 100 ml.
- the present composition preferably comprises 5 to 50 wt.%, more preferably 10 to 40 wt.%, even more preferably 12.4 to 45 wt.%, vegetable lipid, even more preferably 19 to 30 wt.%.
- the composition comprises 40 to 100 wt% vegetable lipids based on total lipids, more preferably 50 to 100 wt%, even more preferably 70 to 99 wt%, even more preferably 75 to 97 wt.%. It is noted therefore that the present composition also may comprise non-vegetable lipids. Suitable and preferred non-vegetable lipids are further specified below.
- lipid is present in the composition in the form of lipid globules, emulsified in the aqueous phase.
- the lipid globules comprise a core and a coating.
- the core typically comprises vegetable fat and preferably at least 90 wt% of the core is formed by triglycerides, more preferably the core essentially consists of triglycerides.
- the coating comprises polar lipids, more preferably at least 30 wt%, even more preferably at least 50 wt%, even more preferably at least 75 wt%, most preferably at least 95 wt% of the coating is formed by polar lipids.
- polar lipids that are preferably present in the composition need necessarily be comprised in the coating, but preferably a major part is.
- Preferably more than 30 wt%, even more preferably more than 50 wt%, more preferably more than 70 wt%, even more preferably more than 85 wt%, most preferably more than 95 wt% of the polar lipids that are present in the composition are comprised in the coating of lipid globules.
- lipid globules not all vegetable lipids that are present in the composition need necessarily be comprised in the core of lipid globules, but preferably a major part is, preferably more than 50 wt%, more preferably more than 70 wt%, even more preferably more than 85 wt%, even more preferably more than 95 wt%, most preferably more than 98 wt% of the vegetable lipids that are present in the composition are comprised in the core of lipid globules.
- the size of the lipid globules of the present invention may be defined by a volume-weighted mode diameter above 1.0 ⁇ , or by a size distribution in such a way that at least 45 volume% of the globules have a diameter between 2 and 12 ⁇ .
- the globules have the volume- weighted mode diameter as defined herein and the size distribution as defined herein.
- the volume-weighted mode diameter of the lipid globules according to the invention is preferably above 3.0 ⁇ , more preferably 4.0 ⁇ or above, preferably between 1.0 and 10 ⁇ , more preferably between 2.0 and 8.0 ⁇ , even more preferably between 3.0 and 8.0 ⁇ , most preferably between 4.0 ⁇ and 8.0 ⁇ .
- the size distribution of the lipid globules according to the invention is such that at least 45 volume %, preferably at least 55 volume %, even more preferably at least 65 volume %, even more preferably at least 75 volume % has a diameter between 2 and 12 ⁇ .
- At least 45 volume %, preferably at least 55 volume %, even more preferably at least 65 volume %, even more preferably at least 75 volume % of the lipid globules have a diameter between 2 and 10 ⁇ . Even more preferably, at least 45 volume %, preferably at least 55 volume %, even more preferably at least 65 volume %, even more preferably at least 75 volume % of the lipid globules have a diameter between 4 and 10 ⁇ .
- the percentage of lipid globules is based on volume of total lipid.
- the mode diameter relates to the diameter which is the most present based on the volume of total lipid, or the peak value in a graphic representation, having on the x-as the diameter and on the y-as the volume (in %).
- the volume of the lipid globule and its size distribution can suitably be determined using a particle size analyzer such as a Mastersizer (Malvern Instruments, Malvern, UK), for example by the method described in Michalski et al, 2001 , Lait 81 : 787-796. Methods to prepare such lipid globules are known in the art, e.g. from WO 2011/1 15491.
- the lipid globules as present in the nutritional composition according to the invention are defined by having a core comprising vegetable lipids and a coating comprising polar lipids.
- a core comprising vegetable lipids and a coating comprising polar lipids.
- Such core/coating structure is further defined above.
- said lipid globules have a size as defined above.
- the lipid fraction preferably comprises polar lipids.
- Polar lipids are amphipathic of nature and include glycerophospholipids, glycosphingolipids, sphingomyelin and/or cholesterol. More preferably the composition comprises phospholipids (the sum of glycerophospholipids and sphingomyelin).
- Polar lipids in the present invention relate to the sum of glycerophospholipids, glycosphingolipids, sphingomyelin and cholesterol.
- polar lipids are preferably present as a coating of the lipid globule. In the context of the present invention, "coating" refers to the outer surface layer of the lipid globule.
- the polar lipids are preferably located on the surface of the lipid globule, whereas these polar lipids are virtually absent in the core of the lipid globule.
- the presence of polar lipids as a coating or outer layer of the lipid globule in the diet administered early in life was found to advantageously result in improving behaviour.
- the present composition preferably comprises glycerophospholipids.
- Glycerophospholipids are a class of lipids formed from fatty acids esterified at the hydroxyl groups on carbon- 1 and carbon-2 of the backbone glycerol moiety and a negatively-charged phosphate group attached to carbon-3 of the glycerol via an ester bond, and optionally a choline group (in case of phosphatidylcholine, PC), a serine group (in case of phosphatidylserine, PS), an ethanolamine group (in case of phosphatidylethanolamine, PE), an inositol group (in case of phosphatidylinositol, PI) or a glycerol group (in case of phosphatidylglycerol, PG) attached to the phosphate group.
- a choline group in case of phosphatidylcholine, PC
- a serine group in case of phosphatidylserine, PS
- an ethanolamine group in case of
- Lysophospholipids are a class of phospholipids with one fatty acyl chain.
- the present composition contains PC, PS, PI and/or PE, more preferably at least PC.
- the present composition preferably comprises phosphospingolipids, preferably sphingomyelin. Sphingomyelins have a phosphorylcholine or phosphorylethanolamine molecule esterified to the 1 -hydroxy group of a ceramide. They are classified as phospholipid as well as sphingolipid, but are not classified as a glycerophospholipid nor as a glycosphingolipid.
- the present composition preferably comprises glycosphingolipids.
- glycosphingolipids as in the present invention particularly refers to glycolipids with an amino alcohol sphingosine.
- the sphingosine backbone is O-linked to a charged headgroup such as ethanolamine, serine or choline backbone.
- the backbone is also amide linked to a fatty acyl group.
- Glycosphingolipids are ceramides with one or more sugar residues joined in a ⁇ -glycosidic linkage at the 1 -hydroxyl position.
- the present composition contains gangliosides, more preferably at least one ganglioside selected from the group consisting of GM3 and GD3.
- Sphingolipids are in the present invention defined as the sum of sphingomyelin and glycosphingolipids.
- Phospholipids are in the present invention defined as the sum of sphingomyelin and glycerophospholipids.
- the phospholipids are derived from milk lipids.
- the weight ratio of phospholipids : glycosphingolipids is from 2: 1 to 10:1, more preferably 2:1 to 5 : 1.
- the present composition further comprises phospholipids and preferably the composition comprises lipid globules with a core comprising the vegetable lipids and a coating comprising said phospholipids.
- the present composition comprises 0.5 to 20 wt.% phospholipids based on total lipid, more preferably 0.5 to 10 wt.%, more preferably 1 to 10 wt.%, even more preferably 1 to 5 wt.%, even more preferably 2 to 10 wt.% even more preferably 2 to 5 wt.%, even more preferably 0.5 to 5 wt.% and even more preferably 1 to 3 wt.% phospholipids based on total lipid.
- the present composition comprises 0.1 to 10 wt.% glycosphingolipids based on total lipid, more preferably 0.5 to 5 wt.%, even more preferably 2 to 4 wt%.
- the present composition comprises 0.5 to 10 wt.% (glycosphingolipids plus phospholipids) based on total lipid, more preferably 1.0 to 10 wt.% (glycosphingolipids plus phospholipids), more preferably 0.5 to 6 wt.% (glycosphingolipids plus phospholipids), more preferably 0.5 to 3.5 wt.% (glycosphingolipids plus phospholipids), more preferably 1.0 to 6 wt.% (glycosphingolipids plus phospholipids), more preferably 1.0 to 3.5 wt.% (glycosphingolipids plus phospholipids) based on total lipid.
- the present composition comprises 0.03 to 3 wt.% sphingomyelin based on total lipid, more preferably 0.1 to 2 wt.%, even more preferably 0.5 to 1 wt%.
- the phospholipids comprise at least 5 wt% sphingomyelin based on total phospholipids, more preferably 10 - 50 wt.%, sphingomyelin based on total phospholipids.
- the present composition preferably further comprises cholesterol.
- the present composition preferably comprises at least 0.005 wt.% cholesterol based on total lipid, more preferably at least 0.02 wt.%, more preferably at least 0.05 wt.%., even more preferably at least 0.1 wt.%.
- the amount of cholesterol does not exceed 10 wt.% based on total lipid, more preferably does not exceed 5 wt.%, even more preferably does not exceed 1 wt.% of total lipid.
- the present composition comprises 0.6 to 25 wt.% polar lipids based on total lipid, wherein the polar lipids are the sum of phospholipids, glycosphingolipids, and cholesterol, more preferably 0.6 to 12 wt.%, more preferably 1 to 10 wt.%, even more preferably 2 to 10 wt%, even more preferably 3.0 to 10 wt.% polar lipids based on total lipid, wherein the polar lipids are the sum of phospholipids, glycosphingolipids, and cholesterol.
- the composition comprises lipid globules with a core comprising the vegetable lipids and a coating comprising said polar lipids.
- the present composition preferably comprises 0.5 to 20 wt.% phospholipids based on total lipid and/or 0.6 to 25 wt.% of polar lipids based on total lipids, wherein polar lipids are the sum of phospholipids, glycosphingolipids and cholesterol, and the composition comprises lipid globules with a core comprising the vegetable lipids and a coating comprising said phospholipids or polar lipids.
- Preferred sources for providing the phospholipids, glycosphingolipids and/or cholesterol are milk fat, buttermilk fat and butter serum fat (such as beta serum fat).
- a preferred source for phospholipids, particularly PC, is soy lecithin and/or sunflower lecithin.
- the present composition preferably comprises phospholipids derived from milk.
- the present composition comprises phospholipids and glycosphingolipids derived from milk.
- the polar lipids are derived from milk.
- Polar lipids derived from milk include the polar lipids isolated from milk lipid, cream lipid, butter serum lipid (beta serum lipid), whey lipid, cheese lipid and/or buttermilk lipid.
- the buttermilk lipid is typically obtained during the manufacture of buttermilk.
- the butter serum lipid or beta serum lipid is typically obtained during the manufacture of anhydrous milk fat from butter.
- the phospholipids, glycosphingolipids and/or cholesterol are obtained from milk cream.
- the composition preferably comprises phospholipids, glycosphingolipids and/or cholesterol from milk of cows, mares, sheep, goats, buffalos, horses and camels. It is most preferred to use a lipid extract isolated from cow's milk.
- the use of polar lipids from milk fat advantageously comprises the polar lipids from milk fat globule membranes, which are more pronounced to the situation in human milk.
- the polar lipids are typically located on the surface of the lipid globule, i.e. as a coating or outer layer.
- a suitable way to determine whether the polar lipids are located on the surface of the lipid globules is laser scanning microscopy (see e.g. example 1 of WO 2011/115491).
- the concomitant use of polar lipids derived from domestic animals milk and trigycerides derived from vegetable lipids therefore enables to manufacture coated lipid globules with a coating more similar to human milk, while at the same time providing an optimal fatty acid profile.
- Suitable commercially available sources for milk polar lipids are BAEF, SM2, SM3 and SM4 powder of Corman, Salibra of Glanbia, and LacProdan MFGM-10 or PL20 from Aria.
- the source of milk polar lipids comprises at least 4 wt.% phospholipids based on total lipid, more preferably 7 to 75 wt.%, most preferably 20 to 70 wt.% phospholipids based on total lipid.
- the weight ratio phospholipids to protein is above 0.10, more preferably above 0.20, even more preferably above 0.3.
- at least 25 wt.%, more preferably at least 40 wt.%, most preferably at least 75 wt.% of the polar lipids is derived from milk polar lipids.
- the composition preferably comprises fatty acids.
- fatty acids refers to monoglycerides, diglycerides, triglycerides and free fatty acids. Preferably, at least triglycerides are present.
- a fatty acid When bound to a glyceride moiety, a fatty acid may also be referred to as a "fatty acyl chain".
- the fatty acids defined hereinbelow may be present bound to a glyceride moiety or in free form, preferably they are bound to a glyceride moiety, more preferably as a triglyceride.
- LA refers to linoleic acid and/or acyl chain (18:2 n6)
- ALA refers to a-linolenic acid and/or acyl chain (18:3 n3)
- LC-PUFA refers to long chain polyunsaturated fatty acids and/or acyl chains comprising at least 20 carbon atoms in the fatty acyl chain and with 2 or more unsaturated bonds
- DHA refers to docosahexaenoic acid and/or acyl chain (22:6, n3)
- EPA refers to eicosapentaenoic acid and/or acyl chain (20:5 n3)
- ARA refers to arachidonic acid and/or acyl chain (20:4 n6)
- DPA refers to docosapentaenoic acid and/or acyl chain (22:5 n3).
- Medium chain fatty acids (MCFA) refer to fatty acids and/or acyl chains with a
- LA preferably is present in a sufficient amount in order to promote a healthy growth and development, yet in an amount as low as possible in view of an unwanted high n6/n3 ratio.
- the composition therefore preferably comprises less than 15 wt.% LA based on total fatty acids, preferably between 5 and 14.5 wt.%, more preferably between 6 and 10 wt.%.
- the composition comprises over 5 wt.% LA based on fatty acids.
- ALA is present in a sufficient amount to promote a healthy growth and development of the infant.
- the present composition therefore preferably comprises at least 1.0 wt.% ALA based on total fatty acids.
- the composition comprises at least 1.5 wt.% ALA based on total fatty acids, more preferably at least 2.0 wt.%.
- the composition comprises less than 10 wt.% ALA, more preferably less than 5.0 wt.% based on total fatty acids.
- the weight ratio LA/ ALA should be well balanced ensuring a normal growth and development. Therefore, the present composition preferably comprises a weight ratio of LA/ALA between 2 and 15, more preferably between 2 and 7, more preferably between 4 and 7, more preferably between 3 and 6, even more preferably between 4 and 5.5, even more preferably between 4 and 5.
- the present composition preferably comprises at least 3 wt.% MCFA based on total fatty acids, more preferably at least 10 wt.%, even more preferably 15 wt.%.
- the present composition advantageously comprises less than 50 wt.% MCFA based on total fatty acids, more preferably less than 40 wt.%, even more preferably less than 25 wt.%.
- the present composition comprises n3 LC-PUFA. n3 LC-PUFAs have been associated with beneficial effects on brain functioning, including cognitive performance. More preferably, the present composition comprises EPA, DPA and/or DHA, even more preferably DHA.
- the content of n3 LC-PUFA in the present composition preferably does not exceed 15 wt.% of the total fatty acid content, preferably does not exceed 10 wt.%, even more preferably does not exceed 5 wt.%.
- the present composition comprises at least 0.2 wt.%, preferably at least 0.5 wt.%, more preferably at least 0.75 wt.%, n3 LC-PUFA of the total fatty acid content.
- the present composition preferably comprises DHA in an amount of 0.1 to 0.6 wt.% based on total fatty acid content.
- the present composition comprises relatively low amounts of ARA.
- the n6 LC-PUFA content preferably does not exceed 5 wt.%, more preferably does not exceed 2.0 wt.%, more preferably does not exceed 0.75 wt.%, even more preferably does not exceed 0.5 wt.%, based on total fatty acids.
- the amount of n6 LC-PUFA is preferably at least 0.02 wt.% more preferably at least 0.05 wt.%, more preferably at least 0.1 wt.% based on total fatty acids, more preferably at least 0.2 wt.%.
- the presence of ARA is advantageous in a composition low in LA since it remedies LA deficiency.
- the presence of, preferably low amounts, of ARA is beneficial in nutrition to be administered to infants below the age of 6 months, since for these infants the infant formulae is generally the only source of nutrition.
- the present composition preferably comprises ARA in an amount of 0.1 to 0.6 wt.% based on total fatty acid content.
- the lipid fraction includes at least vegetable lipid as lipid source.
- a lipid source selected from fish oil (preferably tuna fish oil) and single cell oil (such as algal, microbial oil and fungal oil) is present. These sources of oil are suitable as LC-PUFA sources.
- n3 LC-PUFA single cell oil including algal oil and microbial oil, is used, since these oil sources have an advantageous EPA/DHA ratio.
- fish oil even more preferably tuna fish oil
- the present composition further comprises at least one lipid selected from the group consisting of fish oil, marine oil, algal oil, fungal oil and microbial
- milk lipid as lipid source
- milk lipid comprises many of components that have been found beneficial for infant development.
- milk lipid is a rich source in polar lipids, which are beneficially present in the composition according to the invention.
- Milk lipid includes cream lipid, butter serum lipid (beta serum lipid), whey lipid, cheese lipid, buttermilk lipid, anhydrous milk fat and butter oil.
- the present composition further comprises at least one lipid selected from the group consisting of cream lipid, butter serum lipid (beta serum lipid), whey lipid, cheese lipid, buttermilk lipid, anhydrous milk fat and butter oil.
- the present composition preferably comprises proteins.
- the protein component preferably provides 5 to 15% of the total calories.
- the present composition comprises a protein component that provides 6 to 12% of the total calories.
- More preferably protein is present in the composition below 9% based on calories, more preferably the composition comprises between 7.2 and 8.0% protein based on total calories, even more preferably between 7.3 and 7.7% based on total calories.
- the protein concentration in a nutritional composition is determined by the sum of protein, peptides and free amino acids.
- the composition preferably comprises less than 12 wt.% protein, more preferably between 9.6 to 12 wt.%, even more preferably 10 to 11 wt.%.
- Based on a ready-to-drink liquid product the composition preferably comprises less than 1.5 g protein per 100 ml, more preferably between 1.2 and 1.5 g, even more preferably between 1.25 and 1.35 g.
- the source of the protein should be selected in such a way that the minimum requirements for essential amino acid content are met and satisfactory growth is ensured.
- protein sources based on cows' milk proteins such as whey, casein and mixtures thereof and proteins based on soy, potato or pea are preferred.
- the protein source is preferably based on acid whey or sweet whey, whey protein isolate or mixtures thereof and may include a- lactalbumin and ⁇ -lactoglobulin. More preferably, the protein source is based on acid whey or sweet whey from which caseino-glyco-macropeptide (CGMP) has been removed.
- CGMP caseino-glyco-macropeptide
- Removal of CGMP from sweet whey protein advantageously reduces the threonine content of the sweet whey protein.
- a reduced threonine content is also advantageously achieved by using acid whey.
- the protein source may be supplemented with free amino acids, such as methionine, histidine, tyrosine, arginine and/or tryptophan in order to improve the amino acid profile.
- a-lactalbumin enriched whey protein is used in order to optimize the amino acid profile.
- sweet whey from which CGMP has been removed is used as the protein source, it is preferably supplemented by free arginine in an amount of from 0.1 to 3 wt.% and/or free histidine in an amount of from 0.1 to 1.5 wt.% based on total protein.
- the composition comprises at least 3 wt.% casein based on dry weight.
- the casein is intact and/or non-hydro lyzed.
- the composition preferably comprises digestible carbohydrate.
- the digestible carbohydrate preferably provides 30 to 80% of the total calories of the composition.
- Preferably the digestible carbohydrate provides 40 to 60% of the total calories.
- the composition preferably comprises 3.0 to 30 g digestible carbohydrate per 100 ml, more preferably 6.0 to 20, even more preferably 7.0 to 10.0 g per 100 ml.
- Based on dry weight the present composition preferably comprises 20 to 80 wt.%, more preferably 40 to 65 wt.% digestible carbohydrates.
- Preferred digestible carbohydrate sources are lactose, glucose, sucrose, fructose, galactose, maltose, starch and maltodextrin.
- Lactose is the main digestible carbohydrate present in human milk, and is thus preferably comprised in the present composition.
- the present composition preferably comprises digestible carbohydrate, wherein at least 35 wt.%, more preferably at least 50 wt.%, more preferably at least 75 wt.%, even more preferably at least 90 wt.%, most preferably at least 95 wt.% of the digestible carbohydrate is lactose. Based on dry weight the present composition preferably comprises at least 25 wt.% lactose, preferably at least 40 wt.%.
- the present composition comprises non-digestible carbohydrates, more preferably non- digestible oligosaccharides with a degree of polymerization (DP) between 2 and 250, more preferably 3 and 60.
- DP degree of polymerization
- the non-digestible oligosaccharide is preferably selected from the group consisting of firucto- oligosaccharides (such as inulin), galacto-oligosaccharides (such as transgalacto-oligosaccharides or beta-galacto-oligisaccharides), gluco-oligosaccharides (such as gentio-, nigero- and cyclodextrin-oligosaccharides), arabino-oligosaccharides, mannan-oligosaccharides, xylo- oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno- oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides.
- the composition comprises gum acacia on combination with a non-digestible oligos
- the present composition comprises fructo-oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably galacto-oligosaccharides, most preferably transgalacto-oligosaccharides.
- the composition comprises a mixture of transgalacto-oligosaccharides and fructo-oligosaccharides.
- the present composition comprises galacto-oligosaccharides with a DP of 2-10 and/or fructo- oligosaccharides with a DP of 2-60.
- the galacto-oligosaccharide is preferably selected from the group consisting of transgalacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT.
- the present method comprises the administration of transgalacto- oligosaccharides ([galactose] n -glucose; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, 59 ,60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10).
- Transgalacto- oligosaccharides are for example sold under the trademark VivinalTM (Borculo Domo Ingredients, Netherlands).
- VivinalTM Bosculo Domo Ingredients, Netherlands.
- the saccharides of the transgalacto-oligosaccharides are ⁇ - linked.
- Fructo-oligosaccharide is a non-digestible oligosaccharide comprising a chain of ⁇ linked fructose units with a DP or average DP of 2 to 250, more preferably 10 to 100.
- Fructo- oligosaccharide includes inulin, levan and/or a mixed type of polyfructan.
- An especially preferred fructo-oligosaccharide is inulin.
- Fructo-oligosaccharide suitable for use in the compositions is also already commercially available, e.g. Raftiline®HP (Orafti).
- Uronic acid oligosaccharides are preferably obtained from pectin degradation. Uronic acid oligosaccharides are preferably galacturonic acid oligosaccharides.
- the present composition preferably comprises a pectin degradation product with a DP between 2 and 100.
- the pectin degradation product is prepared from apple pectin, beet pectin and/or citrus pectin.
- the composition comprises transgalacto-oligosaccharide, fructo- oligosaccharide and a pectin degradation product.
- the weight ratio transgalacto-oligosaccharide : fructo-oligosaccharide : pectin degradation product is preferably (20 to 2) : 1 : (1 to 3), more preferably (12 to 7) : 1 : (1 to 2).
- the composition comprises of 80 mg to 2 g non-digestible oligosaccharides per 100 ml, more preferably 150 mg to 1.50 g, even more preferably 300 mg to 1 g per 100 ml. Based on dry weight, the composition preferably comprises 0.25 wt.% to 20 wt.%, more preferably 0.5 wt.% to 10 wt.%, even more preferably 1.5 wt.% to 7.5 wt.%. A lower amount of non-digestible oligosaccharides will be less effective in providing a beneficial prebiotic effect, whereas a too high amount will result in side-effects of bloating and abdominal discomfort.
- the nutritional composition is to be administered to a human subject.
- said human subject is an infant of toddler, more preferably an infant.
- the present composition is preferably administered orally.
- the present composition is preferably administered to the human subject during the first 3 years of life, since at that age cognition and behaviour develops most significantly.
- the nutritional composition is for feeding or is used for feeding a human subject with an age between 0 and 36 months.
- the present composition is advantageously administered to a human of 0 - 24 months, more preferably to a human of 0 - 18 months, most preferably to a human of 0 - 12 months.
- the composition is to be used in healthy, non-obese subjects, preferably in healthy, lean subjects. In a preferred embodiment, the composition is to be used in a healthy subject.
- healthy means that the human subject is not diagnosed with autism, an autistic spectrum disorder or attention deficiency. Attention deficiency includes disorders like ADD and ADHD. Hence in one embodiment according to the present invention, the human subject is not diagnosed with at least one of autism, an autistic spectrum disorder and attention deficiency.
- the beneficial effects in terms of improving behaviour may prolong long after administration has halted, e.g. for the entire childhood or even up to adolescence or adulthood.
- the effect on improving behaviour may thus occur when the subject has an age of 0 - 25 years, preferably 3 months - 18 years, more preferably 6 months - 13 years, most preferably 12 months - 10 years.
- effects that occur during and/or directly after the administration regime i.e. the period during which the subject is administered with the nutritional composition according to the invention, are referred to as "direct" effects.
- the composition is administered to a human subject of 0 - 36 months of age, and is for direct improving behaviour, i.e. at an age of 0 - 36 months.
- the composition is administered to a human subject of 0 - 36 months of age, and is for improving behaviour later-in- life, i.e. at an age above 36 months, preferably above 5 years or above 13 years or even above 18 years, such as 5 - 25 years, 5 - 18 years, 5 - 13 years, 13 - 25 years, 13 - 18 years or 18 - 25 years of age.
- the inventors have surprisingly found that the structure of the lipid fraction, i.e. the presence of lipid globules of a certain size, has a marked effect on improving the behaviour. Surprisingly, these specific aspects of behaviour are improved when subjects are administered with the present composition. These specific aspects of behaviour include (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and/or (d) increasing exploratory behaviour and/or exploratory activity. It was found these aspects of behaviour were increased both direct, i.e. during the administration regime of the nutritional composition according to the invention, and later-in-life, i.e. the improved behaviour was observed after administration of the diet according to the invention had long halted.
- the present invention provides a method for, use for or nutritional composition for use for increasing novel object recognition. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for direct increasing novel object recognition. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing novel object recognition later-in-life. Preferably, the present invention provides a method for, use for or nutritional composition for use for increasing novel object recognition later-in-life. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and/or (d) increasing exploratory behaviour and/or exploratory activity.
- the present invention provides a method for, use for or nutritional composition for use for (a) increasing novel object recognition; and/or (b) increasing the preference for novelty. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for (c) increasing the attention for surroundings; and/or (d) increasing exploratory behaviour and/or exploratory activity.
- the present invention provides a method for, use for or nutritional composition for use for increasing the preference for novelty. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for direct increasing the preference for novelty. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing the preference for novelty later-in-life. Preferably, the present invention provides a method for, use for or nutritional composition for use for increasing the preference for novelty later- in-life.
- the present invention provides a method for, use for or nutritional composition for use for increasing the attention for surroundings. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for direct increasing the attention for surroundings. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing the attention for surroundings later-in- life. Preferably, the present invention provides a method for, use for or nutritional composition for use for direct increasing the attention for surroundings.
- the present invention provides a method for, use for or nutritional composition for use for increasing exploratory behaviour and/or exploratory activity. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for direct increasing exploratory behaviour and/or exploratory activity. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing exploratory behaviour and/or exploratory activity later-in-life. Preferably, the present invention provides a method for, use for or nutritional composition for use for direct increasing exploratory behaviour and/or exploratory activity. Novelty induces arousal in a subject experiencing the novelty. Thus, in the context of the present invention, the improved behaviour is manifest by enhancing the effect of novelty induced arousal.
- the present invention provides a method for, use for or nutritional composition for use for improving behaviour, whereby the improving behaviour is enhancing the effect of novelty induced arousal.
- the improved behaviour is by enhancing the effect of novelty induced arousal on (a) novel object recognition; (b) preference for novelty; (c) attention for surroundings; (d) exploratory behaviour and/or exploratory activity.
- Example 1 Effect on novelty preference of a diet with different lipid globules.
- AIN-93M maintenance semi-synthetic rodent chow
- the experimental diets that were used for weaning were:
- IMF infant milk formula
- This diet comprised 283 g standard IMF per kg, with the standard lipid globule size. The mode based on volume was 0.42 ⁇ . The volume % of lipid globules with a diameter between 2 and 12 ⁇ was 32%. The rest of the diet was ATN-93G protein, carbohydrates and fibre. The amount of soy phospholipid (PL) was 0.13 wt% based on total fat.
- diet 2 contained 30 wt% sphingomyelin, based on total phospholipids in diet 2.
- the amount of cholesterol was 0.03 wt% based on total fat.
- the rest of the diet (about 28 wt%) was AIN-93G protein, carbohydrates and fibre.
- Diet 1 and 2 were identical, except for the lipid fraction, and consisted of 65 wt% carbohydrates (including 15% lactose), 18 % proteins, 7 % lipids, 5 % fibres and 5% vitamin/mineral mix. All lipid was derived from the IMF. The fatty acid composition was very similar between the diets. More information on the fat composition is given in Table 1.
- mice were subjected to a novel object test at postnatal day 35 (during adolescence stage) and at postnatal day 78 (early adulthood).
- This test is widely used in the art of behavioural neuroscience, and is a behavioural procedure to study preference for novelty, measures of recognition and attention.
- the novel object test consisted of three sessions. In the first session the animals were habituated to a square test area (50*50 cm) in which 2 identical objects were present. Animals were allowed to explore the objects for 5 minutes and moved back to their home cage thereafter. After 2 hours, animals were subjected to another habituation to the test area and objects, in which the same objects were present but now one of the objects was placed at a different location than during the initial trial. Again, animals were allowed to explore the objects for 5 minutes and moved to their home cage thereafter. After 2 hours, mice were placed for a third time in the area in which now one of the objects was replaced by an unfamiliar object (novel object), and mice were allowed to explore the objects for 2 minutes.
- Example 2 Effect on exploration of a diet with different lipid globules
- mice were subjected to the T Maze Spontaneous Alternation test on postnatal day 36/37 (adolescence phase).
- the T Maze Spontaneous Alternation test is a well-known behavioural test for measuring exploratory behaviour in rodents.
- the T maze consisted of an elevated T-shaped area (placed horizontally). Mice were placed at the base of the T and were allowed to choose one of the two arms of the T for exploration. Immediately after this, mice were placed at the base of the T maze again and again were allowed to choose one of the two arms of the T for exploration. Animals that now chose the other arm for exploration compared to the first trial (spontaneous alternation) have a high willingness to explore a new environment, i.e. they prefer to visit a new arm of the maze rather than a familiar arm. The procedure was repeated six times in total over two days, and the % of alternation index was calculated over all sessions. The results are shown in table 3.
- ADHD/ADD symptoms may include high novelty seeking and inattention, low/normal novelty seeking is not.
- the present experiments show an improvement in novelty seeking, however, an improvement for ADHD/ADD by diet would be a reduction in novelty seeking and inattention.
- the results obtained are not indicative for establishing a beneficial effect in individuals diagnosed with autism or an autistic spectrum disorder.
- Autistic spectrum disorder symptoms typically are impaired social interactions, impaired verbal social communication, and higher level of repetitive behaviours.
- the present experiments are directed at alterations in spatial surroundings, not in alterations of possibilities for social interactions.
Abstract
The present invention relates to a method for improving behaviour in a human subject, comprising administering a nutritional composition comprising 5 –50 wt% vegetable lipids based on dry weight of the composition to the subject, the nutritional composition comprising lipid globules having (i)a volume-weighted mode diameter above 1.0 micrometerand/or(ii)a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid,wherein improving behaviour is selected from(a) increasing novel object recognition;(b) increasing the preference for novelty;(c) increasing the attention for surroundings;and (d) increasing exploratory behaviour and/or exploratory activity.
Description
LIPID COMPOSITION FOR IMPROVING BEHAVIOUR
FIELD
The present invention relates to nutritional compositions for infants and young children, in particular infant formulae, which comprises specific lipid ingredients for improving specific aspects of behaviour, such as exploratory behaviour and novelty recognition.
BACKGROUND
The nervous system, in particular the brain, plays an essential role in a mammal's life. For example cognitive, emotional, social, sensory, motoric and regulatory functions are mainly determined by the brain. In the western society more and more diseases, disorders and problems with a proper functioning of the brain are becoming recognised. Early nutrition administered during the specific period of infancy when rapid growth and development of the brain occurs, has an imprinting or programming effect and therefore has long term consequences on the brain function. Breast-fed infants score better on visual and developmental tests than do formula-fed infants and they have an improved neurodevelopment compared to formula fed infants. Also long term links have been reported between breast milk feeding and cognitive ability or neurological status later in life. Breast-feeding is the preferred method of feeding infants. However, there are circumstances that make breast-feeding impossible or less desirable. In those cases infant formulae are a good alternative. The composition of modern infant formulae is adapted in such a way that it meets many of the special nutritional requirements of the fast growing and developing infant. Still further improvements can be made. Still it seems that improvements can be made towards the constitution of infant milk formulae.
Fat provides about half of the dietary energy and constitutes the major energy stores in the bodies of infants and young children. Presently, there is growing interest in the quality of the dietary lipid supply during infancy as a major determinant of growth, visual and neural development, and long-term health. For example, the presence of long chain polyunsaturated fatty acids (LC- PUFA), such as docosahexaenoic (DHA) and arachidonic acid (AA) in human milk often has
been designated an important factor for improving the neurological effects, and nowadays infant formula almost always comprise such LC-PUFA.
More recent the role of dairy fat and polar lipids from milk has gained attention. WO 2009/051502 discloses the use of one or more complex lipids including gangliosides for maintaining or increasing cognitive development in a foetal, infant or child subject. WO2006/114790 discloses the use of mixture of polar lipids for improvement of cognitive development in infants or children. WO 2009/138680 disclosed the use of a dairy fat source and a vegetable fat source improvement of brain development, cognitive and behavioural functions in infants and small children. WO2008/005033 discloses infant formulas with gangliosides, phospholipids, sialic acid, docosahexaenoic acid and arachidonic acid for accelerating brain development, neural migration and cognitive development in infants. In all cases a direct diet effect was disclosed, and no longer term effects.
WO 2011/115476 and WO 2011/115491 disclose infant nutrition with lipid globules coated with milk phospholipids for use in improving the fatty acid composition of the membrane and of improvement of cognitive or behavioural performance.
SUMMARY OF THE INVENTION
The inventors surprisingly found direct effects of the diet on novelty recognition and exploratory behaviour using a mouse model wherein a nutritional composition comprising of large lipid globules was administered early in life. Novel object recognition and exploratory behaviour was improved when compared to mice having consumed a nutritional composition with standard, small lipid globules. This is indicative for an increased novel object recognition, increased preference for novelty, increased attention for surroundings and/or increased exploratory behaviour and/or exploratory activity. Surprisingly the effects were even observed later in life after both groups of mice had been subjected to the same standard rodent chow in adulthood. No high fat, Western style diet was applied, so both groups of mice were healthy and lean. Surprisingly, the nutritional composition comprising large lipid globules lead to an improvement in these specific aspects of behaviour. These effects are regulated by specific complex structures of the cognitive brain, such as the cerebral cortex. Without being bound to a theory, it is believed
that the nutritional composition comprising lipid globules as defined hereinbelow beneficially affects such complex structures of the brain.
The invention thus relates to a method for improving behaviour in a human subject, comprising administering a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition to the subject, the nutritional composition comprising lipid globules having (i) a volume-weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour is preferably selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
DETAILED DESCRIPTION
The present invention relates to a method for improving behaviour in a human subject, comprising administering a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition to the subject, the nutritional composition comprising lipid globules having (i) a volume-weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour is selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
The invention can also be worded as the use of a composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition for the manufacture of a nutritional composition for improving behaviour in a human subject, wherein the nutritional composition comprises lipid globules having (i) a volume- weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour is selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
In other words, the invention relates to a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition, for use in improving behaviour, wherein the nutritional composition comprises lipid globules having (i) a volume-weighted mode
diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour is selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
In one aspect the invention relates to a method for improving behaviour by enhancing the effect of novelty induced arousal in a human subject, comprising administering a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition to the subject, the nutritional composition comprising lipid globules having (i) a volume- weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour by enhancing the effect of novelty induced arousal is selected from enhancing the effect of novelty induced arousal on (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity. The invention can also be worded as the use of a composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition for the manufacture of a nutritional composition for improving behaviour by enhancing the effect of novelty induced arousal in a human subject, wherein the nutritional composition comprises lipid globules having (i) a volume-weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour by enhancing the effect of novelty induced arousal is selected from enhancing the effect of novelty induced arousal on (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity. In other words, the invention relates to a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition, for use in improving behaviour by enhancing the effect of novelty induced arousal, wherein the nutritional composition comprises lipid globules having (i) a volume- weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid, wherein improving behaviour by enhancing the effect of novelty induced arousal is selected from enhancing the effect of novelty induced arousal on (a) increasing novel object recognition; (b)
increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity.
In one aspect the invention relates to a method for enhancing the effect of novelty induced arousal on one or more selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity in a human subject, comprising administering a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition to the subject, the nutritional composition comprising lipid globules having (i) a volume- weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid.
The invention can also be worded as the use of a composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition for the manufacture of a nutritional composition for enhancing the effect of novelty induced arousal on one or more selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity in a human subject, wherein the nutritional composition comprises lipid globules having (i) a volume- weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid.
In other words, the invention relates to a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition, for use in enhancing the effect of novelty induced arousal on one or more selected from (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and (d) increasing exploratory behaviour and/or exploratory activity in a human subject, wherein the nutritional composition comprises lipid globules having (i) a volume-weighted mode diameter above 1.0 micrometer and/or (ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid.
The method, use or composition for use may be medical or non-medical. In one embodiment, the method, use or composition for use is medical. In one embodiment, the method, use or composition for use is non-medical.
Nutritional composition
The nutritional composition according to the invention comprises a lipid component, comprising 5 - 50 wt% vegetable lipid based on total dry weight of the composition. The composition comprises lipid in the form of lipid globules. It is preferred that the nutritional composition according to the invention further comprises protein and digestible carbohydrates, more preferably also one or more further components selected from non-digestible carbohydrates, vitamins, minerals, nucleotides is comprised in the nutritional composition according to the invention.
The present composition is preferably particularly suitable for providing the daily nutritional requirements to a human with an age below 36 months, particularly an infant with the age below
24 months, even more preferably an infant with the age below 18 months, most preferably below 12 months of age. Hence, the nutritional composition is for feeding or is used for feeding a human subject. The present composition comprises a lipid, and preferably a protein and preferably a digestible carbohydrate component wherein the lipid component preferably provides 30 to 60 % of total calories, the protein component preferably provides 5 to 20%, more preferably 5 to 15 wt.%, of the total calories and the digestible carbohydrate component preferably provides
25 to 75% of the total calories. Preferably the present composition comprises a lipid component providing 35 to 50% of the total calories, a protein component provides 6 to 12% of the total calories and a digestible carbohydrate component provides 40 to 60% of the total calories. The amount of total calories is determined by the sum of calories derived from protein, lipids and digestible carbohydrates.
The nutritional composition is preferably an infant nutrition or infant food products, more preferably the nutritional composition is an infant formula composition. The present composition is not human breast milk, since the present composition comprises vegetable lipids. The nutritional composition of the invention preferably comprises further beneficial components according to international directives for infant formulae, preferably at least one selected from non-digestible carbohydrates, vitamins, minerals and nucleotides. In one embodiment the composition is a powder suitable for making a liquid composition after reconstitution with an aqueous solution, preferably with water. Preferably the composition is a
powder to be reconstituted with water. It was found that the size and the coating with polar lipids of the lipid globules remained the same after the drying step and subsequent reconstitution.
In order to meet the caloric requirements of the infant, the composition preferably comprises 50 to 200 kcal/100 ml liquid, more preferably 60 to 90 kcal/100 ml liquid, even more preferably 60 to 75 kcal/100 ml liquid. This caloric density ensures an optimal ratio between water and calorie consumption. The osmolarity of the present composition is preferably between 150 and 420 mOsmol/1, more preferably 260 to 320 mOsmol/1. The low osmolarity aims to reduce the gastrointestinal stress. Such stress can induce adipocyte formation.
Preferably the composition is in a liquid form, with a viscosity below 35 mPa.s, more preferably below 6 mPa.s as measured in a Brookfield viscometer at 20°C at a shear rate of 100 s"1. Suitably, the composition is in a powdered from, which can be reconstituted with water to form a liquid, or in a liquid concentrate form, which should be diluted with water. When the composition is in a liquid form, the preferred volume administered on a daily basis is in the range of about 80 to 2500 ml, more preferably about 450 to 1000 ml per day.
Lipid
The present composition comprises lipid. The lipid provides preferably 30 to 60 % of the total calories of the composition, more preferably providing 35 to 55% of the total calories, even more preferably providing 40 to 50% of the total calories. When in liquid form, e.g. as a ready-to-feed liquid, the composition preferably comprises 2.1 to 6.5 g lipid per 100 ml, more preferably 3.0 to 4.0 g per 100 ml. Based on dry weight the present composition preferably comprises 10 to 50 wt.%, more preferably 12.5 to 40 wt.% lipid, even more preferably 19 to 30 wt.% lipid. Lipids include polar lipids (such as phospholipids, glycolipids, sphingomyelin, and cholesterol), monoglycerides, diglycerides, triglycerides and free fatty acids. Preferably the composition comprises at least 75 wt. %, more preferably at least 85 wt.% triglycerides based on total lipids. The lipid of the present invention comprises vegetable lipids. The presence of vegetable lipids advantageously enables an optimal fatty acid profile, high in (poly)unsaturated fatty acids and/or more reminiscent to human milk fat. Using lipids from cow's milk alone, or other domestic mammals, does not provide an optimal fatty acid profile. Preferably the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil (flaxseed oil), rape seed oil (such as colza oil, low erucic acid rape seed oil and canola
oil), salvia oil, perilla oil, purslane oil, lingonberry oil, sea buckthorn oil, hemp oil, sunflower oil, high oleic sunflower oil, safflower oil, high oleic safflower oil, olive oil, black currant seed oil, echium oil, coconut oil, palm oil and palm kernel oil. Preferably the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil, canola oil, coconut oil, sunflower oil and high oleic sunflower oil. Commercially available vegetable lipids are typically offered in the form a continuous oil phase. When in liquid form, e.g. as a ready-to-feed liquid, the composition preferably comprises 1.0 to 7.0 g, more preferably 2.1 to 6.5 g vegetable lipid per 100 ml, more preferably 3.0 to 4.0 g per 100 ml. Based on dry weight the present composition preferably comprises 5 to 50 wt.%, more preferably 10 to 40 wt.%, even more preferably 12.4 to 45 wt.%, vegetable lipid, even more preferably 19 to 30 wt.%. Preferably the composition comprises 40 to 100 wt% vegetable lipids based on total lipids, more preferably 50 to 100 wt%, even more preferably 70 to 99 wt%, even more preferably 75 to 97 wt.%. It is noted therefore that the present composition also may comprise non-vegetable lipids. Suitable and preferred non-vegetable lipids are further specified below.
According to the present invention, lipid is present in the composition in the form of lipid globules, emulsified in the aqueous phase. Preferably, the lipid globules comprise a core and a coating. The core typically comprises vegetable fat and preferably at least 90 wt% of the core is formed by triglycerides, more preferably the core essentially consists of triglycerides. Preferably, the coating comprises polar lipids, more preferably at least 30 wt%, even more preferably at least 50 wt%, even more preferably at least 75 wt%, most preferably at least 95 wt% of the coating is formed by polar lipids. Not all polar lipids that are preferably present in the composition need necessarily be comprised in the coating, but preferably a major part is. Preferably more than 30 wt%, even more preferably more than 50 wt%, more preferably more than 70 wt%, even more preferably more than 85 wt%, most preferably more than 95 wt% of the polar lipids that are present in the composition are comprised in the coating of lipid globules. Not all vegetable lipids that are present in the composition need necessarily be comprised in the core of lipid globules, but preferably a major part is, preferably more than 50 wt%, more preferably more than 70 wt%, even more preferably more than 85 wt%, even more preferably more than 95 wt%, most preferably more than 98 wt% of the vegetable lipids that are present in the composition are comprised in the core of lipid globules.
The size of the lipid globules of the present invention may be defined by a volume-weighted mode diameter above 1.0 μηι, or by a size distribution in such a way that at least 45 volume% of the globules have a diameter between 2 and 12 μπι. It is especially preferred that the globules have the volume- weighted mode diameter as defined herein and the size distribution as defined herein. The volume-weighted mode diameter of the lipid globules according to the invention is preferably above 3.0 μπι, more preferably 4.0 μπι or above, preferably between 1.0 and 10 μπι, more preferably between 2.0 and 8.0 μπι, even more preferably between 3.0 and 8.0 μπι, most preferably between 4.0 μπι and 8.0 μπι. The size distribution of the lipid globules according to the invention is such that at least 45 volume %, preferably at least 55 volume %, even more preferably at least 65 volume %, even more preferably at least 75 volume % has a diameter between 2 and 12 μπι. More preferably, at least 45 volume %, preferably at least 55 volume %, even more preferably at least 65 volume %, even more preferably at least 75 volume % of the lipid globules have a diameter between 2 and 10 μπι. Even more preferably, at least 45 volume %, preferably at least 55 volume %, even more preferably at least 65 volume %, even more preferably at least 75 volume % of the lipid globules have a diameter between 4 and 10 μπι.
The percentage of lipid globules is based on volume of total lipid. The mode diameter relates to the diameter which is the most present based on the volume of total lipid, or the peak value in a graphic representation, having on the x-as the diameter and on the y-as the volume (in %). The volume of the lipid globule and its size distribution can suitably be determined using a particle size analyzer such as a Mastersizer (Malvern Instruments, Malvern, UK), for example by the method described in Michalski et al, 2001 , Lait 81 : 787-796. Methods to prepare such lipid globules are known in the art, e.g. from WO 2011/1 15491.
In an alternative embodiment, the lipid globules as present in the nutritional composition according to the invention, are defined by having a core comprising vegetable lipids and a coating comprising polar lipids. Such core/coating structure is further defined above. Preferably, said lipid globules have a size as defined above.
The lipid fraction preferably comprises polar lipids. Polar lipids are amphipathic of nature and include glycerophospholipids, glycosphingolipids, sphingomyelin and/or cholesterol. More preferably the composition comprises phospholipids (the sum of glycerophospholipids and
sphingomyelin). Polar lipids in the present invention relate to the sum of glycerophospholipids, glycosphingolipids, sphingomyelin and cholesterol. According to the present invention, polar lipids are preferably present as a coating of the lipid globule. In the context of the present invention, "coating" refers to the outer surface layer of the lipid globule. Thus, the polar lipids are preferably located on the surface of the lipid globule, whereas these polar lipids are virtually absent in the core of the lipid globule. The presence of polar lipids as a coating or outer layer of the lipid globule in the diet administered early in life was found to advantageously result in improving behaviour. The present composition preferably comprises glycerophospholipids. Glycerophospholipids are a class of lipids formed from fatty acids esterified at the hydroxyl groups on carbon- 1 and carbon-2 of the backbone glycerol moiety and a negatively-charged phosphate group attached to carbon-3 of the glycerol via an ester bond, and optionally a choline group (in case of phosphatidylcholine, PC), a serine group (in case of phosphatidylserine, PS), an ethanolamine group (in case of phosphatidylethanolamine, PE), an inositol group (in case of phosphatidylinositol, PI) or a glycerol group (in case of phosphatidylglycerol, PG) attached to the phosphate group. Lysophospholipids are a class of phospholipids with one fatty acyl chain. Preferably the present composition contains PC, PS, PI and/or PE, more preferably at least PC. The present composition preferably comprises phosphospingolipids, preferably sphingomyelin. Sphingomyelins have a phosphorylcholine or phosphorylethanolamine molecule esterified to the 1 -hydroxy group of a ceramide. They are classified as phospholipid as well as sphingolipid, but are not classified as a glycerophospholipid nor as a glycosphingolipid. The present composition preferably comprises glycosphingolipids. The term glycosphingolipids as in the present invention particularly refers to glycolipids with an amino alcohol sphingosine. The sphingosine backbone is O-linked to a charged headgroup such as ethanolamine, serine or choline backbone. The backbone is also amide linked to a fatty acyl group. Glycosphingolipids are ceramides with one or more sugar residues joined in a β-glycosidic linkage at the 1 -hydroxyl position. Preferably the present composition contains gangliosides, more preferably at least one ganglioside selected from the group consisting of GM3 and GD3.
Sphingolipids are in the present invention defined as the sum of sphingomyelin and glycosphingolipids. Phospholipids are in the present invention defined as the sum of sphingomyelin and glycerophospholipids. Preferably, the phospholipids are derived from milk lipids. Preferably the weight ratio of phospholipids : glycosphingolipids is from 2: 1 to 10:1, more preferably 2:1 to 5 : 1.
Preferably the present composition further comprises phospholipids and preferably the composition comprises lipid globules with a core comprising the vegetable lipids and a coating comprising said phospholipids. Preferably the present composition comprises 0.5 to 20 wt.% phospholipids based on total lipid, more preferably 0.5 to 10 wt.%, more preferably 1 to 10 wt.%, even more preferably 1 to 5 wt.%, even more preferably 2 to 10 wt.% even more preferably 2 to 5 wt.%, even more preferably 0.5 to 5 wt.% and even more preferably 1 to 3 wt.% phospholipids based on total lipid. Preferably the present composition comprises 0.1 to 10 wt.% glycosphingolipids based on total lipid, more preferably 0.5 to 5 wt.%, even more preferably 2 to 4 wt%. Preferably the present composition comprises 0.5 to 10 wt.% (glycosphingolipids plus phospholipids) based on total lipid, more preferably 1.0 to 10 wt.% (glycosphingolipids plus phospholipids), more preferably 0.5 to 6 wt.% (glycosphingolipids plus phospholipids), more preferably 0.5 to 3.5 wt.% (glycosphingolipids plus phospholipids), more preferably 1.0 to 6 wt.% (glycosphingolipids plus phospholipids), more preferably 1.0 to 3.5 wt.% (glycosphingolipids plus phospholipids) based on total lipid. Preferably the present composition comprises 0.03 to 3 wt.% sphingomyelin based on total lipid, more preferably 0.1 to 2 wt.%, even more preferably 0.5 to 1 wt%. Preferably, the phospholipids comprise at least 5 wt% sphingomyelin based on total phospholipids, more preferably 10 - 50 wt.%, sphingomyelin based on total phospholipids. The present composition preferably further comprises cholesterol. The present composition preferably comprises at least 0.005 wt.% cholesterol based on total lipid, more preferably at least 0.02 wt.%, more preferably at least 0.05 wt.%., even more preferably at least 0.1 wt.%. Preferably the amount of cholesterol does not exceed 10 wt.% based on total lipid, more preferably does not exceed 5 wt.%, even more preferably does not exceed 1 wt.% of total lipid.
Preferably the present composition comprises 0.6 to 25 wt.% polar lipids based on total lipid, wherein the polar lipids are the sum of phospholipids, glycosphingolipids, and cholesterol, more preferably 0.6 to 12 wt.%, more preferably 1 to 10 wt.%, even more preferably 2 to 10 wt%, even more preferably 3.0 to 10 wt.% polar lipids based on total lipid, wherein the polar lipids are the sum of phospholipids, glycosphingolipids, and cholesterol. Preferably, the composition comprises lipid globules with a core comprising the vegetable lipids and a coating comprising said polar lipids.
Thus in one embodiment, the present composition preferably comprises 0.5 to 20 wt.% phospholipids based on total lipid and/or 0.6 to 25 wt.% of polar lipids based on total lipids, wherein polar lipids are the sum of phospholipids, glycosphingolipids and cholesterol, and the composition comprises lipid globules with a core comprising the vegetable lipids and a coating comprising said phospholipids or polar lipids.
Preferred sources for providing the phospholipids, glycosphingolipids and/or cholesterol are milk fat, buttermilk fat and butter serum fat (such as beta serum fat). A preferred source for phospholipids, particularly PC, is soy lecithin and/or sunflower lecithin. The present composition preferably comprises phospholipids derived from milk. Preferably the present composition comprises phospholipids and glycosphingolipids derived from milk. Preferably also cholesterol is obtained from milk. Preferably the polar lipids are derived from milk. Polar lipids derived from milk include the polar lipids isolated from milk lipid, cream lipid, butter serum lipid (beta serum lipid), whey lipid, cheese lipid and/or buttermilk lipid. The buttermilk lipid is typically obtained during the manufacture of buttermilk. The butter serum lipid or beta serum lipid is typically obtained during the manufacture of anhydrous milk fat from butter. Preferably the phospholipids, glycosphingolipids and/or cholesterol are obtained from milk cream. The composition preferably comprises phospholipids, glycosphingolipids and/or cholesterol from milk of cows, mares, sheep, goats, buffalos, horses and camels. It is most preferred to use a lipid extract isolated from cow's milk. The use of polar lipids from milk fat advantageously comprises the polar lipids from milk fat globule membranes, which are more reminiscent to the situation in human milk. The polar lipids are typically located on the surface of the lipid globule, i.e. as a coating or outer layer. A suitable way to determine whether the polar lipids are located on the surface of the lipid globules is laser scanning microscopy (see e.g. example 1 of WO 2011/115491). The concomitant use of
polar lipids derived from domestic animals milk and trigycerides derived from vegetable lipids therefore enables to manufacture coated lipid globules with a coating more similar to human milk, while at the same time providing an optimal fatty acid profile. Suitable commercially available sources for milk polar lipids are BAEF, SM2, SM3 and SM4 powder of Corman, Salibra of Glanbia, and LacProdan MFGM-10 or PL20 from Aria. Preferably the source of milk polar lipids comprises at least 4 wt.% phospholipids based on total lipid, more preferably 7 to 75 wt.%, most preferably 20 to 70 wt.% phospholipids based on total lipid. Preferably the weight ratio phospholipids to protein is above 0.10, more preferably above 0.20, even more preferably above 0.3. Preferably at least 25 wt.%, more preferably at least 40 wt.%, most preferably at least 75 wt.% of the polar lipids is derived from milk polar lipids.
The composition preferably comprises fatty acids. The term "fatty acids" refers to monoglycerides, diglycerides, triglycerides and free fatty acids. Preferably, at least triglycerides are present. When bound to a glyceride moiety, a fatty acid may also be referred to as a "fatty acyl chain". The fatty acids defined hereinbelow may be present bound to a glyceride moiety or in free form, preferably they are bound to a glyceride moiety, more preferably as a triglyceride. In this context, LA refers to linoleic acid and/or acyl chain (18:2 n6); ALA refers to a-linolenic acid and/or acyl chain (18:3 n3); LC-PUFA refers to long chain polyunsaturated fatty acids and/or acyl chains comprising at least 20 carbon atoms in the fatty acyl chain and with 2 or more unsaturated bonds; DHA refers to docosahexaenoic acid and/or acyl chain (22:6, n3); EPA refers to eicosapentaenoic acid and/or acyl chain (20:5 n3); ARA refers to arachidonic acid and/or acyl chain (20:4 n6); DPA refers to docosapentaenoic acid and/or acyl chain (22:5 n3). Medium chain fatty acids (MCFA) refer to fatty acids and/or acyl chains with a chain length of 6, 8 or 10 carbon atoms.
LA preferably is present in a sufficient amount in order to promote a healthy growth and development, yet in an amount as low as possible in view of an unwanted high n6/n3 ratio. The composition therefore preferably comprises less than 15 wt.% LA based on total fatty acids, preferably between 5 and 14.5 wt.%, more preferably between 6 and 10 wt.%. Preferably the composition comprises over 5 wt.% LA based on fatty acids. Preferably ALA is present in a sufficient amount to promote a healthy growth and development of the infant. The present
composition therefore preferably comprises at least 1.0 wt.% ALA based on total fatty acids. Preferably the composition comprises at least 1.5 wt.% ALA based on total fatty acids, more preferably at least 2.0 wt.%. Preferably the composition comprises less than 10 wt.% ALA, more preferably less than 5.0 wt.% based on total fatty acids. The weight ratio LA/ ALA should be well balanced ensuring a normal growth and development. Therefore, the present composition preferably comprises a weight ratio of LA/ALA between 2 and 15, more preferably between 2 and 7, more preferably between 4 and 7, more preferably between 3 and 6, even more preferably between 4 and 5.5, even more preferably between 4 and 5. The present composition preferably comprises at least 3 wt.% MCFA based on total fatty acids, more preferably at least 10 wt.%, even more preferably 15 wt.%. The present composition advantageously comprises less than 50 wt.% MCFA based on total fatty acids, more preferably less than 40 wt.%, even more preferably less than 25 wt.%. Preferably the present composition comprises n3 LC-PUFA. n3 LC-PUFAs have been associated with beneficial effects on brain functioning, including cognitive performance. More preferably, the present composition comprises EPA, DPA and/or DHA, even more preferably DHA. Since a low concentration of DHA, DPA and/or EPA is already effective and normal growth and development are important, the content of n3 LC-PUFA in the present composition, preferably does not exceed 15 wt.% of the total fatty acid content, preferably does not exceed 10 wt.%, even more preferably does not exceed 5 wt.%. Preferably the present composition comprises at least 0.2 wt.%, preferably at least 0.5 wt.%, more preferably at least 0.75 wt.%, n3 LC-PUFA of the total fatty acid content. In one embodiment the present composition preferably comprises DHA in an amount of 0.1 to 0.6 wt.% based on total fatty acid content.
As the group of n6 fatty acids, especially arachidonic acid (ARA) and LA as its precursor, counteracts the group of n3 fatty acids, especially DHA and EPA and ALA as their precursor, the present composition comprises relatively low amounts of ARA. The n6 LC-PUFA content preferably does not exceed 5 wt.%, more preferably does not exceed 2.0 wt.%, more preferably does not exceed 0.75 wt.%, even more preferably does not exceed 0.5 wt.%, based on total fatty acids. Since ARA is important for optimal functional membranes in infants, the amount of n6
LC-PUFA is preferably at least 0.02 wt.% more preferably at least 0.05 wt.%, more preferably at least 0.1 wt.% based on total fatty acids, more preferably at least 0.2 wt.%. The presence of ARA is advantageous in a composition low in LA since it remedies LA deficiency. The presence of, preferably low amounts, of ARA is beneficial in nutrition to be administered to infants below the age of 6 months, since for these infants the infant formulae is generally the only source of nutrition. In one embodiment the present composition preferably comprises ARA in an amount of 0.1 to 0.6 wt.% based on total fatty acid content.
The lipid fraction includes at least vegetable lipid as lipid source. In addition, a lipid source selected from fish oil (preferably tuna fish oil) and single cell oil (such as algal, microbial oil and fungal oil) is present. These sources of oil are suitable as LC-PUFA sources. Preferably as a source of n3 LC-PUFA single cell oil, including algal oil and microbial oil, is used, since these oil sources have an advantageous EPA/DHA ratio. More preferably fish oil (even more preferably tuna fish oil) is used as a source of n3 LC-PUFA since fish oil has a higher EPA concentration. Thus in one embodiment the present composition further comprises at least one lipid selected from the group consisting of fish oil, marine oil, algal oil, fungal oil and microbial
Also preferred is to include milk lipid as lipid source, as milk lipid comprises many of components that have been found beneficial for infant development. Also, milk lipid is a rich source in polar lipids, which are beneficially present in the composition according to the invention. Milk lipid includes cream lipid, butter serum lipid (beta serum lipid), whey lipid, cheese lipid, buttermilk lipid, anhydrous milk fat and butter oil. Thus in one embodiment the present composition further comprises at least one lipid selected from the group consisting of cream lipid, butter serum lipid (beta serum lipid), whey lipid, cheese lipid, buttermilk lipid, anhydrous milk fat and butter oil.
Protein
The present composition preferably comprises proteins. The protein component preferably provides 5 to 15% of the total calories. Preferably the present composition comprises a protein component that provides 6 to 12% of the total calories. More preferably protein is present in the composition below 9% based on calories, more preferably the composition comprises between
7.2 and 8.0% protein based on total calories, even more preferably between 7.3 and 7.7% based on total calories. The protein concentration in a nutritional composition is determined by the sum of protein, peptides and free amino acids. Based on dry weight the composition preferably comprises less than 12 wt.% protein, more preferably between 9.6 to 12 wt.%, even more preferably 10 to 11 wt.%. Based on a ready-to-drink liquid product the composition preferably comprises less than 1.5 g protein per 100 ml, more preferably between 1.2 and 1.5 g, even more preferably between 1.25 and 1.35 g.
The source of the protein should be selected in such a way that the minimum requirements for essential amino acid content are met and satisfactory growth is ensured. Hence protein sources based on cows' milk proteins such as whey, casein and mixtures thereof and proteins based on soy, potato or pea are preferred. In case whey proteins are used, the protein source is preferably based on acid whey or sweet whey, whey protein isolate or mixtures thereof and may include a- lactalbumin and β-lactoglobulin. More preferably, the protein source is based on acid whey or sweet whey from which caseino-glyco-macropeptide (CGMP) has been removed. Removal of CGMP from sweet whey protein advantageously reduces the threonine content of the sweet whey protein. A reduced threonine content is also advantageously achieved by using acid whey. Optionally the protein source may be supplemented with free amino acids, such as methionine, histidine, tyrosine, arginine and/or tryptophan in order to improve the amino acid profile. Preferably a-lactalbumin enriched whey protein is used in order to optimize the amino acid profile. Using protein sources with an optimized amino acid profile closer to that of human breast milk enables all essential amino acids to be provided at reduced protein concentration, below 9 % based on calories, preferably between 7.2 and 8.0% based on calories and still ensure a satisfactory growth. If sweet whey from which CGMP has been removed is used as the protein source, it is preferably supplemented by free arginine in an amount of from 0.1 to 3 wt.% and/or free histidine in an amount of from 0.1 to 1.5 wt.% based on total protein.
Preferably the composition comprises at least 3 wt.% casein based on dry weight. Preferably the casein is intact and/or non-hydro lyzed.
Digestible carbohydrates
The composition preferably comprises digestible carbohydrate. The digestible carbohydrate preferably provides 30 to 80% of the total calories of the composition. Preferably the digestible
carbohydrate provides 40 to 60% of the total calories. When in liquid form, e.g. as a ready-to- feed liquid, the composition preferably comprises 3.0 to 30 g digestible carbohydrate per 100 ml, more preferably 6.0 to 20, even more preferably 7.0 to 10.0 g per 100 ml. Based on dry weight the present composition preferably comprises 20 to 80 wt.%, more preferably 40 to 65 wt.% digestible carbohydrates.
Preferred digestible carbohydrate sources are lactose, glucose, sucrose, fructose, galactose, maltose, starch and maltodextrin. Lactose is the main digestible carbohydrate present in human milk, and is thus preferably comprised in the present composition. The present composition preferably comprises digestible carbohydrate, wherein at least 35 wt.%, more preferably at least 50 wt.%, more preferably at least 75 wt.%, even more preferably at least 90 wt.%, most preferably at least 95 wt.% of the digestible carbohydrate is lactose. Based on dry weight the present composition preferably comprises at least 25 wt.% lactose, preferably at least 40 wt.%.
Non-digestible carbohydrates
Preferably the present composition comprises non-digestible carbohydrates, more preferably non- digestible oligosaccharides with a degree of polymerization (DP) between 2 and 250, more preferably 3 and 60. These non-digestible oligosaccharides advantageously improve intestinal microbiota.
The non-digestible oligosaccharide is preferably selected from the group consisting of firucto- oligosaccharides (such as inulin), galacto-oligosaccharides (such as transgalacto-oligosaccharides or beta-galacto-oligisaccharides), gluco-oligosaccharides (such as gentio-, nigero- and cyclodextrin-oligosaccharides), arabino-oligosaccharides, mannan-oligosaccharides, xylo- oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno- oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides. Preferably the composition comprises gum acacia on combination with a non-digestible oligosaccharide.
Preferably the present composition comprises fructo-oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably galacto-oligosaccharides, most preferably transgalacto-oligosaccharides. In a preferred embodiment the composition comprises a mixture of transgalacto-oligosaccharides and fructo-oligosaccharides. Preferably the present composition comprises galacto-oligosaccharides with a DP of 2-10 and/or fructo-
oligosaccharides with a DP of 2-60. The galacto-oligosaccharide is preferably selected from the group consisting of transgalacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT. In a particularly preferred embodiment the present method comprises the administration of transgalacto- oligosaccharides ([galactose]n-glucose; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, 59 ,60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10). Transgalacto- oligosaccharides (TOS) are for example sold under the trademark Vivinal™ (Borculo Domo Ingredients, Netherlands). Preferably the saccharides of the transgalacto-oligosaccharides are β- linked.
Fructo-oligosaccharide is a non-digestible oligosaccharide comprising a chain of β linked fructose units with a DP or average DP of 2 to 250, more preferably 10 to 100. Fructo- oligosaccharide includes inulin, levan and/or a mixed type of polyfructan. An especially preferred fructo-oligosaccharide is inulin. Fructo-oligosaccharide suitable for use in the compositions is also already commercially available, e.g. Raftiline®HP (Orafti).
Uronic acid oligosaccharides are preferably obtained from pectin degradation. Uronic acid oligosaccharides are preferably galacturonic acid oligosaccharides. Hence the present composition preferably comprises a pectin degradation product with a DP between 2 and 100. Preferably the pectin degradation product is prepared from apple pectin, beet pectin and/or citrus pectin. Preferably the composition comprises transgalacto-oligosaccharide, fructo- oligosaccharide and a pectin degradation product. The weight ratio transgalacto-oligosaccharide : fructo-oligosaccharide : pectin degradation product is preferably (20 to 2) : 1 : (1 to 3), more preferably (12 to 7) : 1 : (1 to 2).
Preferably, the composition comprises of 80 mg to 2 g non-digestible oligosaccharides per 100 ml, more preferably 150 mg to 1.50 g, even more preferably 300 mg to 1 g per 100 ml. Based on dry weight, the composition preferably comprises 0.25 wt.% to 20 wt.%, more preferably 0.5 wt.% to 10 wt.%, even more preferably 1.5 wt.% to 7.5 wt.%. A lower amount of non-digestible oligosaccharides will be less effective in providing a beneficial prebiotic effect, whereas a too high amount will result in side-effects of bloating and abdominal discomfort.
Target group
In the context of the present invention, the nutritional composition is to be administered to a human subject. Preferably, said human subject is an infant of toddler, more preferably an infant. The present composition is preferably administered orally. The present composition is preferably administered to the human subject during the first 3 years of life, since at that age cognition and behaviour develops most significantly. In one embodiment of the use according to the present invention, the nutritional composition is for feeding or is used for feeding a human subject with an age between 0 and 36 months. The present composition is advantageously administered to a human of 0 - 24 months, more preferably to a human of 0 - 18 months, most preferably to a human of 0 - 12 months. In a preferred embodiment, the composition is to be used in healthy, non-obese subjects, preferably in healthy, lean subjects. In a preferred embodiment, the composition is to be used in a healthy subject. In the context of the present invention, healthy means that the human subject is not diagnosed with autism, an autistic spectrum disorder or attention deficiency. Attention deficiency includes disorders like ADD and ADHD. Hence in one embodiment according to the present invention, the human subject is not diagnosed with at least one of autism, an autistic spectrum disorder and attention deficiency.
Although the age of the human subject to which the present composition is administered is preferably from 0 - 36 months, the beneficial effects in terms of improving behaviour may prolong long after administration has halted, e.g. for the entire childhood or even up to adolescence or adulthood. The effect on improving behaviour may thus occur when the subject has an age of 0 - 25 years, preferably 3 months - 18 years, more preferably 6 months - 13 years, most preferably 12 months - 10 years. Within the context of the present inventions, effects that occur during and/or directly after the administration regime, i.e. the period during which the subject is administered with the nutritional composition according to the invention, are referred to as "direct" effects. On the other hand, effects that occur and/or prolong until after administration has halted, such as at least 3 months, preferably at least 6 months, more preferably 1 - 10 years, most preferably 2 - 5 years after termination of the administration regime, are referred to as "later-in-life" effects. In a particularly preferred embodiment, the composition is administered to a human subject of 0 - 36 months of age, and is for direct improving behaviour, i.e. at an age of 0 - 36 months. In an alternative particularly preferred embodiment, the composition is administered to a human subject of 0 - 36 months of age, and is for improving behaviour later-in-
life, i.e. at an age above 36 months, preferably above 5 years or above 13 years or even above 18 years, such as 5 - 25 years, 5 - 18 years, 5 - 13 years, 13 - 25 years, 13 - 18 years or 18 - 25 years of age. Application
The inventors have surprisingly found that the structure of the lipid fraction, i.e. the presence of lipid globules of a certain size, has a marked effect on improving the behaviour. Surprisingly, these specific aspects of behaviour are improved when subjects are administered with the present composition. These specific aspects of behaviour include (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and/or (d) increasing exploratory behaviour and/or exploratory activity. It was found these aspects of behaviour were increased both direct, i.e. during the administration regime of the nutritional composition according to the invention, and later-in-life, i.e. the improved behaviour was observed after administration of the diet according to the invention had long halted. It will be understood that (a) increasing novel object recognition and (b) increasing the preference for novelty are highly interrelated, as well as (c) increasing the attention for surroundings and (d) increasing exploratory behaviour and/or exploratory activity are. The improved novelty index as shown in example 1 evidences that aspects (a) and (b) are indeed improved upon administration of the nutritional composition according to the invention. The improved exploration in the T- maze as shown in example 2 evidences that aspects (c) and (d) are indeed improved upon administration of the nutritional composition according to the invention. It should however be noted that novelty preference and recognition relies on the inherent exploratory behaviour of the subject, and that the T-maze spontaneous alteration test of example 2 requires novelty recognition. Thus, aspects (a) - (d) are intrinsically linked.
In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing novel object recognition. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for direct increasing novel object recognition. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing novel object recognition later-in-life. Preferably, the present invention provides a method for, use for or nutritional composition for use for increasing novel object recognition later-in-life.
In one embodiment, the present invention provides a method for, use for or nutritional composition for use for (a) increasing novel object recognition; (b) increasing the preference for novelty; (c) increasing the attention for surroundings; and/or (d) increasing exploratory behaviour and/or exploratory activity. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for (a) increasing novel object recognition; and/or (b) increasing the preference for novelty. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for (c) increasing the attention for surroundings; and/or (d) increasing exploratory behaviour and/or exploratory activity.
In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing the preference for novelty. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for direct increasing the preference for novelty. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing the preference for novelty later-in-life. Preferably, the present invention provides a method for, use for or nutritional composition for use for increasing the preference for novelty later- in-life.
In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing the attention for surroundings. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for direct increasing the attention for surroundings. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing the attention for surroundings later-in- life. Preferably, the present invention provides a method for, use for or nutritional composition for use for direct increasing the attention for surroundings.
In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing exploratory behaviour and/or exploratory activity. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for direct increasing exploratory behaviour and/or exploratory activity. In one embodiment, the present invention provides a method for, use for or nutritional composition for use for increasing exploratory behaviour and/or exploratory activity later-in-life. Preferably, the present invention provides a method for, use for or nutritional composition for use for direct increasing exploratory behaviour and/or exploratory activity.
Novelty induces arousal in a subject experiencing the novelty. Thus, in the context of the present invention, the improved behaviour is manifest by enhancing the effect of novelty induced arousal. Hence in one embodiment the present invention provides a method for, use for or nutritional composition for use for improving behaviour, whereby the improving behaviour is enhancing the effect of novelty induced arousal. Preferably the improved behaviour is by enhancing the effect of novelty induced arousal on (a) novel object recognition; (b) preference for novelty; (c) attention for surroundings; (d) exploratory behaviour and/or exploratory activity.
EXAMPLES
Example 1: Effect on novelty preference of a diet with different lipid globules.
Experimental groups were obtained from C57B1/6J dams and housed in a controlled environment with ad libitum access to food and water unless specified otherwise. Breeding pairs were fed semi-synthetic diets (AIN93G; Research Diet Services, Wijk bij Duurstede, The Netherlands). At postnatal day (P) 2, litters were culled to 6 pups/dam and litters were randomly assigned at PI 6 to either of the two experimental diets containing a control IMF (Control IMF) or the experimental IMF (Concept IMF). Male pups were weaned at P21 onto their respective diets and single housed. At P45 the mice were switched to a maintenance semi-synthetic rodent chow (AIN-93M) until dissection. From day 45 to day 101 all pups were ad libitum fed the same synthetic rodent chow diet (AIN-93M).
The experimental diets that were used for weaning were:
1) an infant milk formula (IMF) based control diet (IMF1). This diet comprised 283 g standard IMF per kg, with the standard lipid globule size. The mode based on volume was 0.42 μηι. The volume % of lipid globules with a diameter between 2 and 12 μιη was 32%. The rest of the diet was ATN-93G protein, carbohydrates and fibre. The amount of soy phospholipid (PL) was 0.13 wt% based on total fat.
2) an IMF based experimental diet with large lipid globules (FMF2). The mode based on volume was 4,72 μπι. The volume % of lipid globules with a diameter between 2 and 12 μιη was 62%. This diet comprised 283 g experimental IMF per kg. The IMF comprised 4 g phospholipid from buttermilk serum (Friesland Campina) per kg IMF. The amount of soy PL was 0.13 wt% based
on total fat. The amount of milk PL was 1.49 wt% based on total fat, with 0.49 wt% sphingomyelin based on total fat. In total, diet 2 contained 30 wt% sphingomyelin, based on total phospholipids in diet 2. The amount of cholesterol was 0.03 wt% based on total fat. The rest of the diet (about 28 wt%) was AIN-93G protein, carbohydrates and fibre.
Diet 1 and 2 were identical, except for the lipid fraction, and consisted of 65 wt% carbohydrates (including 15% lactose), 18 % proteins, 7 % lipids, 5 % fibres and 5% vitamin/mineral mix. All lipid was derived from the IMF. The fatty acid composition was very similar between the diets. More information on the fat composition is given in Table 1.
Table 1 : Fat composition of experimental diets
The male mice were subjected to a novel object test at postnatal day 35 (during adolescence stage) and at postnatal day 78 (early adulthood). This test is widely used in the art of behavioural
neuroscience, and is a behavioural procedure to study preference for novelty, measures of recognition and attention.
The novel object test consisted of three sessions. In the first session the animals were habituated to a square test area (50*50 cm) in which 2 identical objects were present. Animals were allowed to explore the objects for 5 minutes and moved back to their home cage thereafter. After 2 hours, animals were subjected to another habituation to the test area and objects, in which the same objects were present but now one of the objects was placed at a different location than during the initial trial. Again, animals were allowed to explore the objects for 5 minutes and moved to their home cage thereafter. After 2 hours, mice were placed for a third time in the area in which now one of the objects was replaced by an unfamiliar object (novel object), and mice were allowed to explore the objects for 2 minutes. The time that was spent exploring the objects was measured and a preference index for novel object was calculated by the formula (exploration time new object - exploration time familiar object)/(total time explored objects). The results are shown in Table 2. Measures of activity (cm moved and velocity) were not different between diet groups during the novel object recognition test
Table 2: preference index for novel object in mice weaned on chow with different fat composition
* p<0.05 compared to IMF1 (one way ANOVA)
As can be deduced from table 2, at day 35 preference of novelty is increased in mice consuming the diet with the experimental fat composition. Interestingly at day 78, at adulthood when both groups of mice have consumed the same standard chow diet for 33 days, the preference for novelty is increased statistically significantly in the experimental diet group compared to the control diet group, which indicates that the effects of the experimental fat composition on preference to novelty are persistent into adulthood, when the experimental diet was administered during infancy.
This increased preference for novelty is also indicative for increased novel object recognition.
Example 2: Effect on exploration of a diet with different lipid globules
In the same experiment as described under example 1, mice were subjected to the T Maze Spontaneous Alternation test on postnatal day 36/37 (adolescence phase). The T Maze Spontaneous Alternation test is a well-known behavioural test for measuring exploratory behaviour in rodents.
The T maze consisted of an elevated T-shaped area (placed horizontally). Mice were placed at the base of the T and were allowed to choose one of the two arms of the T for exploration. Immediately after this, mice were placed at the base of the T maze again and again were allowed to choose one of the two arms of the T for exploration. Animals that now chose the other arm for exploration compared to the first trial (spontaneous alternation) have a high willingness to explore a new environment, i.e. they prefer to visit a new arm of the maze rather than a familiar arm. The procedure was repeated six times in total over two days, and the % of alternation index was calculated over all sessions. The results are shown in table 3.
Table 3 : Percent alternation in mice weaned on chow with different fat composition
* p<0.05 compared to IMF1 (one way ANOVA)
As can be seen in table 3, the percentage of alternation, indicative of preference for exploration of a novel environment, is significantly increased at day at day 36/37 in adolescent mice consuming the fat composition of the present invention.
This increased exploration behaviour is also indicative for increased attention for surroundings.
It is noted the observed effects in these examples are not particularly of benefit in individuals diagnosed with ADHD or ADD. Although ADHD/ADD symptoms may include high novelty seeking and inattention, low/normal novelty seeking is not. The present experiments show an improvement in novelty seeking, however, an improvement for ADHD/ADD by diet would be a reduction in novelty seeking and inattention.
Likewise, the results obtained are not indicative for establishing a beneficial effect in individuals diagnosed with autism or an autistic spectrum disorder. Autistic spectrum disorder symptoms typically are impaired social interactions, impaired verbal social communication, and higher level of repetitive behaviours. The present experiments are directed at alterations in spatial surroundings, not in alterations of possibilities for social interactions.
Claims
1. Method for improving behaviour in a human subject, comprising administering a nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition to the subject, the nutritional composition comprising lipid globules having:
i) a volume- weighted mode diameter above 1.0 micrometer, and/or
ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid,
wherein improving behaviour is selected from:
a. increasing novel object recognition;
b. increasing the preference for novelty;
c. increasing the attention for surroundings;
d. increasing exploratory behaviour and/or exploratory activity.
2. Method according to claim 1 wherein the composition further comprises 0.5 - 10 wt.% phospholipids based on total lipid.
3. Method according to claim 2 wherein the phospholipids are derived from the milk fat globule membrane.
4. Method according to claim 2 or 3 wherein the phospholipids comprise at least 5 wt% sphingomyelin based on total phospholipids.
5. Method according to any one of claim 2 to 4, wherein the phospholipids are located at the surface of the lipid globule.
6. Method according to any one of the preceding claims, wherein the lipid globules have a volume- weighted mode diameter above 1.0 micrometer, preferably 2.0 - 8.0 micrometer.
7. Method according to any one of the preceding claims, wherein improving behaviour is by enhancing the effect of novelty induced arousal on (a) novel object recognition; (b) preference for novelty; (c) attention for surroundings; (d) exploratory behaviour and/or exploratory activity.
8. Method according to any one of the preceding claims, wherein the nutritional composition further comprises protein and digestible carbohydrate and preferably at least one further component selected from non-digestible carbohydrates, vitamins, minerals, and nucleotides.
9. Method according to any one of the preceding claims, wherein the human subject to whom the nutritional composition is administered has an age of 36 months or below.
10. Method according to any one of the preceding claims, wherein the human subject is not diagnosed with autism, an autistic spectrum disorder or attention deficiency.
11. Method according to any one of the preceding claims wherein the improving behaviour occurs when the human subject is above 36 months of age, preferably above 5 years of age.
12. Method according to any one of the preceding claims wherein the human subject is a non- obese subject, preferably a lean subject.
13. Use of a composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition for the manufacture of a nutritional composition for improving behaviour in a human subject, wherein the nutritional composition comprises lipid globules having: i) a volume- weighted mode diameter above 1.0 micrometer, and/or
ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid,
wherein improving behaviour is selected from:
a. increasing novel object recognition;
b. increasing the preference for novelty;
c. increasing the attention for surroundings; and
d. increasing exploratory behaviour and/or exploratory activity
14. Nutritional composition comprising 5 - 50 wt% vegetable lipids based on dry weight of the composition, for use in improving behaviour, wherein the nutritional composition comprises lipid globules having:
i) a volume- weighted mode diameter above 1.0 micrometer, and/or
ii) a diameter of 2 to 12 micrometer in an amount of at least 45 volume% based on total lipid,
wherein improving behaviour is selected from:
a. increasing novel object recognition;
b. increasing the preference for novelty;
c. increasing the attention for surroundings; and
d. increasing exploratory behaviour and/or exploratory activity
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580056055.7A CN107072277A (en) | 2014-08-15 | 2015-08-17 | lipid composition for improving behavior |
US15/503,930 US20170273343A1 (en) | 2014-08-15 | 2015-08-17 | Lipid composition for improving behaviour |
EP15787042.9A EP3179868B1 (en) | 2014-08-15 | 2015-08-17 | Lipid composition for improving behaviour |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14181194.3 | 2014-08-15 | ||
EP14181194 | 2014-08-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016024864A1 true WO2016024864A1 (en) | 2016-02-18 |
Family
ID=51302951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2015/050580 WO2016024864A1 (en) | 2014-08-15 | 2015-08-17 | Lipid composition for improving behaviour |
Country Status (5)
Country | Link |
---|---|
US (1) | US20170273343A1 (en) |
EP (1) | EP3179868B1 (en) |
CN (1) | CN107072277A (en) |
TR (1) | TR201900900T4 (en) |
WO (1) | WO2016024864A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018104512A1 (en) | 2016-12-09 | 2018-06-14 | N.V. Nutricia | Nutritional composition for improving cell membranes |
US11376222B2 (en) | 2013-11-01 | 2022-07-05 | N.V. Nutricia | Lipid composition for improving body composition during catch-up growth |
US11389403B2 (en) | 2015-10-15 | 2022-07-19 | N.V. Nutricia | Infant formula with special lipid architecture for promoting healthy growth |
WO2023232882A1 (en) | 2022-05-31 | 2023-12-07 | N.V. Nutricia | Infant formula for improving cognitive development |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040022922A1 (en) * | 2002-06-16 | 2004-02-05 | David Rutenberg | Infant formula supplemented with phospholipids |
WO2006114790A2 (en) | 2005-04-28 | 2006-11-02 | Enzymotec Ltd. | Polar lipid mixtures, their preparation and uses |
US20080003330A1 (en) * | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Infant formulas for early brain development |
WO2009051502A1 (en) | 2007-10-19 | 2009-04-23 | Steven Charles Hodgkinson | Methods of maintaining or increasing growth or cognitive development |
WO2009138680A2 (en) | 2008-04-29 | 2009-11-19 | Groupe Lactalis | Dairy fat baby food |
US20110206743A1 (en) * | 2008-09-02 | 2011-08-25 | N.V. Nutricia | Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids |
WO2011115476A1 (en) | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
-
2015
- 2015-08-17 CN CN201580056055.7A patent/CN107072277A/en active Pending
- 2015-08-17 EP EP15787042.9A patent/EP3179868B1/en active Active
- 2015-08-17 US US15/503,930 patent/US20170273343A1/en not_active Abandoned
- 2015-08-17 TR TR2019/00900T patent/TR201900900T4/en unknown
- 2015-08-17 WO PCT/NL2015/050580 patent/WO2016024864A1/en active Application Filing
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040022922A1 (en) * | 2002-06-16 | 2004-02-05 | David Rutenberg | Infant formula supplemented with phospholipids |
WO2006114790A2 (en) | 2005-04-28 | 2006-11-02 | Enzymotec Ltd. | Polar lipid mixtures, their preparation and uses |
US20110294757A1 (en) * | 2005-04-28 | 2011-12-01 | Avidor Shulman | Polar lipid mixtures, their preparation and uses |
US20080003330A1 (en) * | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Infant formulas for early brain development |
WO2008005033A1 (en) | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Infant formulas for early brain development |
WO2009051502A1 (en) | 2007-10-19 | 2009-04-23 | Steven Charles Hodgkinson | Methods of maintaining or increasing growth or cognitive development |
WO2009138680A2 (en) | 2008-04-29 | 2009-11-19 | Groupe Lactalis | Dairy fat baby food |
US20110206743A1 (en) * | 2008-09-02 | 2011-08-25 | N.V. Nutricia | Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids |
WO2011115476A1 (en) | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
WO2011115491A1 (en) | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes |
US20130096087A1 (en) * | 2010-03-17 | 2013-04-18 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes |
Non-Patent Citations (1)
Title |
---|
MICHALSKI ET AL., LAIT, vol. 81, 2001, pages 787 - 796 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11376222B2 (en) | 2013-11-01 | 2022-07-05 | N.V. Nutricia | Lipid composition for improving body composition during catch-up growth |
US11389403B2 (en) | 2015-10-15 | 2022-07-19 | N.V. Nutricia | Infant formula with special lipid architecture for promoting healthy growth |
WO2018104512A1 (en) | 2016-12-09 | 2018-06-14 | N.V. Nutricia | Nutritional composition for improving cell membranes |
EP3874959A1 (en) | 2016-12-09 | 2021-09-08 | N.V. Nutricia | Nutritional composition for use in improving cognitive performance and/or preventing cognitive impairment |
US11632974B2 (en) | 2016-12-09 | 2023-04-25 | N.V. Nutricia | Nutritional composition for improving cell membranes |
WO2023232882A1 (en) | 2022-05-31 | 2023-12-07 | N.V. Nutricia | Infant formula for improving cognitive development |
Also Published As
Publication number | Publication date |
---|---|
EP3179868A1 (en) | 2017-06-21 |
CN107072277A (en) | 2017-08-18 |
EP3179868B1 (en) | 2018-10-31 |
TR201900900T4 (en) | 2019-02-21 |
US20170273343A1 (en) | 2017-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10548869B2 (en) | Infant nutrition for improving fatty acid composition of brain membranes | |
EP2542101B1 (en) | Modulation of post-prandial fat absorption | |
WO2010068086A1 (en) | Nutritional compositions with large lipid globule size | |
WO2013191542A1 (en) | Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat | |
WO2010027258A1 (en) | Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids | |
AU2016338822B2 (en) | Infant formula with special lipid architecture for promoting healthy growth | |
EP3362061A1 (en) | Infant formula with milk fat for promoting healthy growth | |
EP3179868B1 (en) | Lipid composition for improving behaviour | |
US11632974B2 (en) | Nutritional composition for improving cell membranes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15787042 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
REEP | Request for entry into the european phase |
Ref document number: 2015787042 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015787042 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15503930 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |